Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
about
NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells.Integrating interventional oncology in the treatment of liver tumors.Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunityPercutaneous ablation for HCC eligible to transplantation: providing more opportunities of remission in the context of graft shortage
P2860
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
@en
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
@nl
type
label
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
@en
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
@nl
prefLabel
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
@en
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
@nl
P50
P1476
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
@en
P2093
Olivier Sutter
P304
P356
10.1016/J.JHEP.2017.10.004
P577
2017-10-12T00:00:00Z